Natixis Advisors LLC boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 18.1% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 169,363 shares of the biopharmaceutical company's stock after buying an additional 25,912 shares during the period. Natixis Advisors LLC's holdings in Gilead Sciences were worth $14,199,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in GILD. Manning & Napier Advisors LLC purchased a new position in shares of Gilead Sciences during the second quarter worth approximately $25,328,000. Legal & General Group Plc increased its holdings in shares of Gilead Sciences by 0.8% in the second quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company's stock valued at $851,743,000 after purchasing an additional 93,068 shares during the period. IRON Financial LLC acquired a new stake in shares of Gilead Sciences during the third quarter worth about $830,000. Wealth Enhancement Advisory Services LLC boosted its position in Gilead Sciences by 13.1% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 286,116 shares of the biopharmaceutical company's stock valued at $19,630,000 after buying an additional 33,162 shares during the last quarter. Finally, Cetera Investment Advisers raised its position in Gilead Sciences by 127.6% during the 1st quarter. Cetera Investment Advisers now owns 213,901 shares of the biopharmaceutical company's stock worth $15,668,000 after buying an additional 119,909 shares during the last quarter. Institutional investors own 83.67% of the company's stock.
Insider Buying and Selling
In other Gilead Sciences news, insider Merdad Parsey sold 25,590 shares of the business's stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total value of $2,341,485.00. Following the transaction, the insider now owns 99,599 shares in the company, valued at $9,113,308.50. The trade was a 20.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the sale, the insider now owns 78,127 shares of the company's stock, valued at approximately $6,545,480.06. This represents a 27.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 56,947 shares of company stock worth $4,968,674 in the last three months. 0.16% of the stock is currently owned by insiders.
Wall Street Analysts Forecast Growth
A number of equities analysts have weighed in on the company. Royal Bank of Canada lifted their price objective on Gilead Sciences from $81.00 to $84.00 and gave the company a "sector perform" rating in a research note on Monday. Piper Sandler raised their price objective on shares of Gilead Sciences from $95.00 to $105.00 and gave the stock an "overweight" rating in a research note on Thursday, November 7th. Leerink Partners raised shares of Gilead Sciences from a "market perform" rating to an "outperform" rating and increased their price target for the stock from $74.00 to $96.00 in a report on Monday, October 21st. The Goldman Sachs Group upped their price objective on shares of Gilead Sciences from $74.00 to $84.00 and gave the stock a "neutral" rating in a research report on Thursday, November 7th. Finally, Leerink Partnrs upgraded Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Monday, October 21st. Twelve equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and four have issued a strong buy rating to the stock. According to data from MarketBeat, Gilead Sciences presently has a consensus rating of "Moderate Buy" and a consensus target price of $94.45.
Get Our Latest Report on GILD
Gilead Sciences Trading Down 0.4 %
NASDAQ:GILD opened at $88.29 on Thursday. The stock has a market cap of $110.03 billion, a price-to-earnings ratio of 984.78, a PEG ratio of 2.72 and a beta of 0.17. The business has a fifty day moving average of $87.15 and a 200-day moving average of $76.52. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $98.90. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping the consensus estimate of $1.58 by $0.44. The firm had revenue of $7.55 billion for the quarter, compared to analysts' expectations of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. Gilead Sciences's revenue for the quarter was up 7.0% compared to the same quarter last year. During the same period in the previous year, the business earned $2.29 earnings per share. Equities analysts predict that Gilead Sciences, Inc. will post 4.38 earnings per share for the current year.
Gilead Sciences Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Stockholders of record on Friday, December 13th will be paid a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 3.49%. The ex-dividend date of this dividend is Friday, December 13th. Gilead Sciences's dividend payout ratio is presently 3,422.22%.
About Gilead Sciences
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Featured Articles
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
